Library

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2021, T. 121, No. 6

Summary:
the state of cancellation of alcohol develops with the refusal of drinking alcohol, after prolonged or short -lived, but their massive use, is manifested by somatic symptoms and, in some cases, is complicated by the development of alcoholic seizures, alcoholic hallucinosis and alcohol delirium, which can create a threat to patients. The leading neurochemical factors underlying alcohol cancellation and its complications are the insufficient cerebral content of the GABA and the excessive activity of glutamate, which matters to therapy. First -line preparations in the treatment of alcohol and alcoholic delirium cancellation are benzodiazepines with maximum pharmacological similarities with ethanol. As an alternative to benzodiazepines and in addition to them, especially in the case of protracted delirium with therapeutic resistance, other drugs, including barbiturates, antiepileptic drugs, propofols, dexemedetomidine and antipsychoticism, can be used. Certain prospects in the treatment of alcohol cancellation syndrome are associated with ethylmethylhydroxypyridine with a succinate, which has some pharmacological similarity with benzodiazepines. Key words: alcohol disorders, alcohol cancellation syndrome, alcohol convulsions, alcoholic hallucinosis, alcoholic delirium, benzodiazepines.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2020, T. 120, No. 5

Summary:
A review of modern literature is presented regarding the use of Mexidol (ethylmethylhydroxypyridine succinate) in the treatment of mental (in particular, addictive) disorders. The possibility of its prescription for the correction of negative psychopathological symptoms, neurocognitive deficiency, manifestations of neuroleptic syndrome (including its extrapyramidal disorders) in the treatment of antipsychotics in patients with schizophrenic spectrum, insomnic disorders in the complex therapy of border mental disorders is shown. The possibilities of the use of the drug Mexidol in the treatment of addictive pathology, as well as the consequences of intoxication caused by alcohol and other psychoactive (in particular, narcotic) substances deserve. Key words: mental disorders, addictive pathology, Mexidol, treatment, complex therapy.

The purpose of the study . Assessment of the dynamics of the functional activity of the structures of the brain that provide cognitive functions in patients with encephalopathy in acute poisoning with neurotoxic substances at the rehabilitation stage.

Material and methods. 56 patients were examined. The main group was 40 patients, for the treatment of which the intravenous drip administration of Mexidol was used - 10 patients, a combination of Mexidol with non -drug methods of treatment in the form of mesodyeencephalic modulation (MDM) - 10 patients, hyperbaric oxygenation (HBO) - 10 patients and combinations of MDM and HBO - 10 patients. The comparison group was 16 people. All patients were recorded by EEGs caused by auditory (associated event) potentials (SSP) and carried out neuropsychological testing. Results and conclusion. EEG changes noted in all their severity examined with their great severity, and the dominance of signs of violation of the functional activity of the formations of
the diencephalic or mesodyeencephalous level was noted. After the treatment in the main group, positive dynamics was detected in 60% of cases. In 80% of cases, positive dynamics was noted when using a combination of Mexidol, MDM and HBO. Negative dynamics in the main group was noted in 5 (12.5%) cases, while it was more often detected when only Mexidol was used in the treatment process. The results of the primary neuropsychological study showed that in the main group in 97.5% of cases and in 100% of patients of the comparison group, violations of cognitive activity of varying degrees of severity were detected. After the treatment in patients of the main group, 62.5% improved indicators for neuropsychological tests, there was a reduction in the latent period of components N200, P300, an increase in the amplitude of the caused potentials. Thus, the use of patients with encephalopathy in acute poisoning with various neurotoxicants at the stage of rehabilitation of Mexidol, HBO and MDM leads to an improvement in the indicators that reflect the functional state of the brain as a whole and the state of cognitive functions.

Keywords: encephalopathy, acute neurotoxicant poisoning, electroencephalography, auditory -related potential (P300), psychophysiological testing, mexidol, mesodyeencephalmic modulation, hyperbaric oxygenation.

Place of publication:
Journal of Neurology and Psychiatry, 2, 2013

Summary:
70 patients with panic disorder (PR), 30 men and 40 women were examined, whose average age was 34.5 ± 1.8 years. All patients were distinguished by the presence of dissocation disorders. Patients, depending on the characteristics of therapy, were divided into 2 groups - control and basic. Patients of the control group were treated only with an antidepressant (freedin at a dose of 150 mg per day); Mexidol (375 mg per day) was appointed to patients of the main group to antidepressant.

Place of publication:
Bulletin of experimental biology and medicine, 2012, Appendix 1

Summary:
In the treatment of patients with opium drug addiction by Mexidol and convulsan, the symptoms of withdrawal and postbustified disorders were reduced faster and to a greater extent than in the treatment according to the standard methodology. Patients used to become capable of socio-non-norment behavior, to constructive and productive actions in the treatment and rehabilitation process. Key words: Mexidol, convulsan, lamotridine, drug addiction, withdrawal disorders.

Place of publication:
Bulletin of experimental biology and medicine, 2006, Appendix 1

Summary:
Mexidol is an effective, economical treatment for a comprehensive treatment of convulsive syndrome of withdrawal genesis, prevents recurrence of convulsive attacks, significantly improves overall well -being and cognitive functions for a shorter period of time than other nootropic drugs. Key words: withdrawal, injury, convulsive syndrome, cognitive functions, Mexidol.

Place of publication:
Journal of Neurology and Psychiatry, 11, 2006

Summary:
the results of the clinical assessment of the effectiveness and tolerance of Mexidol are presented with its intravenous drip administration within 5-7 days in 50 cases of complicated alcohol delirium by Mexidol. The clinical condition of the patients and the dynamics of laboratory data were evaluated in comparison with the control group of patients on basic therapy without Mexidol. It was established that the use of Mexidol allows you to stop psychosis as early as possible, which in turn leads to a decrease in secondary complications and mortality. Key words: Mexidol, antioxidant, antihypoxant, alcoholic delirium, stopping.

Place of publication:
Bulletin of experimental biology and medicine, 2006, Appendix 1

Summary:
Mexidol was used in the treatment of various options for alcohol withdrawal syndrome. Thanks to the expressed vegetostabilizing and sedative effects of Mexidol’s therapy, it was more effective than complex traditional therapy in the removal of neurovegetative and psychopathological manifestations. Key words: alcoholism, withdrawal syndrome, Mexidol.

Place of publication:
Bulletin of experimental biology and medicine, 2006, Appendix 1

Summary:
the clinical effectiveness and validity of the use of Mexidol in the complex therapy of patients with post -traumatic stress disorders with typical psychopathological symptoms has been studied. The dynamics of changes in not only quantitative (experimental-psychological) indicators, but also of qualitative (clinical) features were taken into account. With the use of Mexidol, emotional lability decreased in 6% of cases, the intensity of headaches - in 36%, the level of alcoholization - in 37%, the mood background increased in 59% of cases, the level of asthenization was normalized in 82.6% of cases, the level of anxiety decreased to the norm In 70% of cases. Normalizing the processes in the central nervous system, increasing the adaptive reserves of the body, Mexol, enhances effectiveness and reduces side effects of the use of antidepressants and benzodiazepines. Thus, Mexidol is a promising drug in the treatment of post -traumatic stress disorders. Key words: post -traumatic stress disorder, Mexidol, adaptive reserves, social fences, anxiolytic activity.

Place of publication:
Bulletin of experimental biology and medicine, 2006, Appendix 1

Summary:
30 patients with neurotic conditions and the predominance of depressive, anxious, hysterical symptoms were examined. The effect of Mexidol was evaluated on the level of depression, anxiety, memory and attention. The positive effect of the drug is noted that contributes to social adaptation and improve the quality of life of patients. Key words: neurosis, depression, therapy, neurometabolic products, Mexidol.

Place of publication:
cardiology and cardiovascular surgery, 2023, T. 16, No. 4

Summary:
Purpose of the study. Assessment of the effect of Mexidol, as part of the complex therapy of heart failure for 10 weeks on cognitive status, quality parameters, asthenic syndrome and anxiety level in patients with XN II-III functional class (according to NYHA classification). Material and methods. An open randomized study included 60 comorbide patients with coronary heart disease (coronary heart disease) and stable chronic heart failure (COL) with cognitive disorders (KN) ≤24 points on the Montreal scale for evaluating cognitive functions (MOCA). The average age of patients was 73.4 ± 8.6 years, 53% - male, the average release fraction of 43.5 ± 10.6%. 30 patients were included in the standard therapy group with the additional purpose of Mexidol (500 mg intravenously dropped 1 time per day for 14 days, then 250 mg 3 times a day 8 weeks) and 30 patients in a standard therapy group. Initially and at the end of the study, an assessment of the effect of therapy on the cognitive status of patients on the Montreal scale of assessment of cognitive functions (Mosa), anxiety level on the Bek scale, the degree of severity and the dynamics of asthenic syndrome on the subjective scale of astheny assessment (MFI-20), and health profiles according to the questionnaire was carried out EQ-5D-5L and quality parameters based on the results of the Essence on the Minnesotsky (MlHFQ), Kansas (Kansas City CardiOMYOPATHY QUESTIONNAIRA, KCCQ) and the SF36 questionnaire “Evaluation of the quality of life”. Results. In patients who received Mexidol, in addition to standard therapy, a reliable improvement of cognitive function by 21%was revealed, a decrease in anxiety-by 38%and the severity of asthenic syndrome-by 12%, improve the overall health of the EQ-5D-5L questionnaire-by 25%by 25% , as well as the qualities of life according to the Minnesotsky questionnaire - by 48%, according to the Kansas questionnaire - by 39%. Conclusion. Mexidol, when adding to standard therapy of patients with XN II-III, functional class, reliably improves cognitive status, quality parameters, reduces the severity of asthenic syndrome and anxiety level. Key words: heart failure, cognitive status, quality of life, Mexidol.

Place of publication:
cardiology and cardiovascular surgery, 2022, T. 15, No. 6

Summary:
The development of preventive measures to reduce the risk of developing cognitive deficiency is named after the main priorities of medicine. Cardiovascular diseases and cognitive disorders, on the one hand, have similar risk factors, such as obesity, smoking, dyslipidemia, insufficient physical activity, low level of education, and, on the other hand, the presence of atrial fibrillation (FP), arterial hypertension (hypertension (hypertension ), heart failure (CH), chronic kidney disease, diabetes contributes to the progression of cognitive impairment. In the era of patient-oriented medicine, choosing the optimal treatment regimen of hypertension, FP, SN, it is necessary to take into account the potential possibilities of certain regimes of therapy in the prevention of cognitive impairment. This article is devoted to the review of existing therapeutic strategies to prevent the development of cognitive deficiency in patients with a cardiological profile. Keywords: cognitive disorders, dementia, arterial hypertension, atrial fibrillation, heart failure, Mexidol.

Cardiovascular diseases (CCZ) remain the most common among chronic non-infectious diseases. In 2020, approximately 19.1 million deaths around the world were associated with the SVD, and their prevalence with the amendment to age amounted to 7354.1 cases per 100 thousand people. Given the increasing life expectancy and, accordingly, the share of elderly people in the structure of the population, an increase in the prevalence of the CVD is further expected. The functions of the brain and cardiovascular system (CCC) are closely interconnected. So, it is well known that diseases of the brain, such as a stroke, can lead to damage to the myocardium. On the other hand, cognitive functions directly depend on the state of CCC. Therefore, quite often to describe the pathology of the brain in patients with SVD, the term “cerebrovascular diseases” (CVP) is used. CVP combines a group of diseases due to pathological changes in cerebral vessels. The CVP is a manifestation and complication of various SVDs, such as dyslipidemia, arterial hypertension (hypertension), diabetes (diabetes), etc., leading to acute or chronic disturbances in cerebral circulation. Clinically the CVP can manifest by acute cerebrovascular accident in the form of a stroke or transient ischemic attack or have a chronic course, leading to the development of vascular cognitive impairment (KN).

Place of publication:
cardiology and cardiovascular surgery, 2020, T. 13, No. 5

Summary:
Purpose of the study. To study the effects of Mexidol on the level of n-cowline sodium sodium hormone (NT-PROBNP), the severity of oxidative stress, inflammatory reaction and endothelial dysfunction in patients with II-II-III functional class (FC) in the classification of NYHA during consistent intravenous and oral introduction Mexidol for 13 weeks against the background of standard basic therapy. Material and methods. The study included 44 patients with chemical and heart failure of the II -III functional class according to NYHA, a release fraction of less than 50%. The average age was 65.5 ± 11.8 years, 75% were male patients. 21 patients were included in the basic therapy group with the additional purpose of Mexidol (1000 mg intravenously dropped 1 time per day for 7 days, then 250 mg 3 times a day 12 weeks) and 23 patients in the basic therapy group. 34 patients completely completed the study. 10 patients were made in the form of a phone call in connection with an epidemic environment. Initially, on the 7th day and at the 13th week, an assessment of the level of the N-Container's sodium sodium hormone (NT-PROBNP), oxidative stress (the amount of low-minor dyalldehyde (MDA) and the activity of superoxidsmutase (SOD)), an assessment of the level of n-cow cerebral hormone was held. an inflammatory reaction (level of C-reactive protein (CRB), factor of necrosis of tumors α (FNOα)), as well as the content of homocysteine ​​and level of cystatin C. Results. In patients who received Mexidol in addition to basic therapy, a reliably more pronounced decrease in the level of NT-PROBNP, a decrease in the concentration of MDA, a decrease in the level of SRB and FNOα and an increase in the activity of SOD on the 7th day, and after 13 weeks of therapy compared to the group that received therapy was revealed Only basic therapy. Conclusion. When adding to the basic therapy of patients with chemical and heart failure II-III, the NT-PROBNP level has a reliable antioxidant activity, reduces the severity of the inflammatory reaction, slows down the increase in homocysteine, and does not affect the kidney function (cystatin C). Keywords: chronic brain ischemia, heart failure, oxidative stress, antioxidants, N-connection propeptide of cerebral hormone (NT-PROBNP), mild dialdehyde, superoxidsmutase, SRB, ethylmethylhydroxypirinidine sequicine, mexed.

One of the most common diseases associated with cognitive disorders in elderly patients is chronic heart failure, leading to a cognitive decrease in 25-80% of cases. The review discusses the role of vascular lesions of various calibers and general mechanisms of impaired microcirculation in the development of both cardiac and chronic cerebrovascular insufficiency. It is believed that their understanding can help in the development of more effective approaches in the treatment of cardiovascular and cerebrovascular pathology. Keywords: cognitive disorders, vascular dementia, heart failure, microcirculation disorders, endothelial dysfunction.

Place of publication:
Journal of Neurology and Psychiatry, 9, 2018

Summary:
The article presents a review of domestic and foreign literature on the influence of arterial hypertension (AH) on the risk of cognitive impairment. The data of major studies are considered, indicating the relationship of blood pressure and risk of developing vascular dementia and Alzheimer's disease in elderly and senile people, as well as the role of antihypertensive therapy. Evidence of the negative impact of the presence of hypertension in the middle age on the state of cognitive functions in the elderly is presented. The importance of interdisciplinary approach to the treatment of cognitive impairment with cardiologists and/or therapists together with neurologists, as well as comprehensive treatment regimens, including correction of risk factors and neuroprotective therapy, is emphasized. Keywords: arterial hypertension, cognitive disorders, vascular dementia, Alzheimer disease, antihypertensive therapy.